Evidence map›Paper›PMID 34552731›Full record

ArticleClinical case reports2021

A non-cytotoxic regimen of decitabine to treat refractory T-cell large granular lymphocytic leukemia.

Misam Zawit, Carmelo Gurnari, Simona Pagliuca, Hassan Awada, Jaroslaw P Maciejewski, Yogen Saunthararajah

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Misam ZawitTranslational Hematology and Oncology Research Department Taussig Cancer Center Cleveland Clinic Cleveland OH USA.
Carmelo GurnariTranslational Hematology and Oncology Research Department Taussig Cancer Center Cleveland Clinic Cleveland OH USA.
Simona PagliucaTranslational Hematology and Oncology Research Department Taussig Cancer Center Cleveland Clinic Cleveland OH USA.
Hassan AwadaTranslational Hematology and Oncology Research Department Taussig Cancer Center Cleveland Clinic Cleveland OH USA.
Jaroslaw P MaciejewskiTranslational Hematology and Oncology Research Department Taussig Cancer Center Cleveland Clinic Cleveland OH USA.
Yogen SaunthararajahTranslational Hematology and Oncology Research Department Taussig Cancer Center Cleveland Clinic Cleveland OH USA.ORCID https://orcid.org/0000-0002-9757-1031
Cleveland Clinic · USUniversity of Rome Tor Vergata · IT

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
Targeting Enzymatic Regulation of Fetal Hemoglobin RepressionP01HL146372 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ENGEL, JAMES DOUGLAS · 2019 to 2023
$10.9M
Therapeutic Implications of Molecular Defects in Bone Marrow FailureR35HL135795 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2017 to 2023
$5.7M
Novel Spliceosomal Defects in Myelodysplastic SyndromesR01HL132071 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2016 to 2019
$2.4M
RNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic TargetR01HL123904 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI JANKOWSKY, ECKHARD, MACIEJEWSKI, JAROSLAW P. · 2015 to 2018
$2.1M
Investigations of Consequences of U2AF1 Mutations in MDSR01HL118281 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2013 to 2017
$1.9M
Imaging Liver Cancer ProliferationR01CA204373 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI LEE, ZHENGHONG, SAUNTHARARAJAH, YOGEN · 2016 to 2021
$1.8M
NCI NIH HHS P30 CA043703NCI NIH HHS R01 CA204373NHLBI NIH HHS P01 HL146372NHLBI NIH HHS R01 HL118281NHLBI NIH HHS R01 HL123904NHLBI NIH HHS R01 HL132071NHLBI NIH HHS R35 HL135795
6 · The paper itself

Abstract

We report on a novel, successful, non-cytotoxic therapy to treat multiply-refractory T-LGL in an elderly patient.

Indexed as

decitabinefrail patientsnon‐cytotoxic regimenT‐cell large granular lymphocytic leukemia

Identifiers

PMID34552731
PMCPMC8443408
OpenAlexW3161503403

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.